(VIANEWS) – The NASDAQ opens in less than five hours and Xenetic Biosciences‘s pre-market value is already 18.86% up.
Xenetic Biosciences’s last close was $0.40, 64.34% below its 52-week high of $1.13.
The last session, NASDAQ finished with Xenetic Biosciences (XBIO) sliding 6.28% to $0.40. NASDAQ dropped 1.08% to $12,080.51, after two sequential sessions in a row of losses, on what was an all-around bearish trend exchanging session.
About Xenetic Biosciences
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Earnings Per Share
As for profitability, Xenetic Biosciences has a trailing twelve months EPS of $-0.47.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -40.9%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Xenetic Biosciences’s EBITDA is 6.09.
Sales Growth
Xenetic Biosciences’s sales growth is 5.4% for the present quarter and 5.5% for the next.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 8.3% and 42.1%, respectively.
Volume
Today’s last reported volume for Xenetic Biosciences is 22817 which is 46.39% below its average volume of 36363.
More news about Xenetic Biosciences (XBIO).
